Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGD007 in Metastatic Colorectal Carcinoma
NCT02248805Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Oct 2014
- Primary completion
- Jul 2018
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of MGD007 in colorectal cancer (CRC) (4 arms), sponsored by MacroGenics. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Started Oct 2014; status: completed.
02
Drugs
MGD007
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02248805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248805.